论文部分内容阅读
目的探讨吉西他滨(GEM)联合5-氟尿嘧啶(5-Fu)与奈达铂(NDP)时辰化疗晚期食管癌的近期疗效及不良反应。方法 GEM2000 mg/m2分d1、8静脉点滴,5-Fu 2500 mg/m2分d1～5(15:00-18:00)微量泵静脉输注,奈达铂75 mg/m2分d1-3静脉点滴,于5-Fu前2 h应用亚叶酸钙200 mg/d,21 d为1个周期,2个周期后评价疗效。结果治疗周期中位值为4.5个周期,CR2例,PR14例,SD5例,PD5例,总有效率(CR+PR)为61.5%(16/26)。主要不良反应是骨髓抑制和胃肠道反应。无Ⅳ度骨髓抑制,口腔炎、肝肾毒性等均较轻。结论吉西他滨(GEM)联合5-氟尿嘧啶(5-Fu)与奈达铂(NDP)时辰化疗晚期食管癌疗效确切,安全性好。
Objective To investigate the short-term effects and side effects of gemcitabine combined with 5-fluorouracil and NDP on advanced esophageal cancer. Methods GEM2000 mg / m2 d1,8 intravenous drip, 5-Fu 2500 mg / m2 d1 ~ 5 (15: 00-18: 00) intravenous infusion pump, nedaplatin 75 mg / m2 d1-3 vein Drip, leucovorin 200 mg / d 2 h before 5-Fu, 21 d for 1 cycle, 2 cycles after the evaluation of the effect. Results The median treatment cycle was 4.5 cycles. There were CR2, PR14, SD5 and PD5, and the total effective rate (CR + PR) was 61.5% (16/26). The main adverse reactions are myelosuppression and gastrointestinal reactions. No degree of myelosuppression, stomatitis, liver and kidney toxicity are lighter. Conclusions Gemcitabine (GEM) combined with 5-fluorouracil (5-Fu) and nedaplatin (NDP) in the chemotherapy of advanced esophageal cancer is effective and safe.